Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201103353 Principal Investigator: Waqar, Saiama
Title: A Randomized Double Blind Phase III efficacy & safety study of PF-00299804 vs.erlotinib for the treatment of Advanced NSCLC following progression after, of intollerance to, at least one prior chemotherapy
Phase: III Disease Site: Lung
Participating Site(s):
 
Main Campus
Map and Directions		 St. Peters
Map and Directions		 West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this research study is to compare the good and bad effects of an investigational drug called dacomitinib with erlotinib, a drug that is already approved and is commonly used to treat patients with advanced non-small cell lung cancer (NSCLC) who have had at least one prior chemotherapy regimen.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)